Cerebral Edema
0 original drugs 0
Novel Drugs
16
Reformulations
0
Active Trials
0
Drug Targets
Phase 3 Readouts Pro
1 active Phase 3 trial with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Clinical Pipeline by Phase
3 industry-sponsored trials across 2 sponsors
Novel Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (16 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
BRONCHITOL
PHARMAXIS EUROPE
T10 2020
ARIDOL KIT
PHARMAXIS EUROPE
T3 2010
ARIDOL
PHARMAXIS EUROPE
T3 2010
MANNITOL 20% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1987
MANNITOL 10% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1987
MANNITOL 15% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1987
MANNITOL 5% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1987
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Pfizer
T5 1976
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 20% IN WATER
Baxter
T5 1964
OSMITROL 5% IN WATER
Baxter
T5 1964
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 15% IN WATER
Baxter
T5 1964
OSMITROL 10% IN WATER
Baxter
T5 1964
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs